Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 176 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Tuberculosis Clear all
Terminated No phase listed Observational Results available

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

NCT04518228
View directory record Official record
Conditions
HIV, Tuberculosis
Interventions
Bictegravir (BIC), Tenofovir alafenamide (TAF), Long-acting injectable formulation of cabotegravir (CAB LA), Dolutegravir (DTG), Atazanavir/ritonavir (ATV/r), Darunavir/ritonavir (DRV/r), Lopinavir/ritonavir (LPV/r), Cobicistat, Ritonavir, First-Line TB Treatment, Second-Line TB Treatment, Doravirine (DOR)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 20, 2026, 2:23 PM EDT
Completed No phase listed Observational

Expression of Tuberculosis in the Lung

NCT00201253
View directory record Official record
Conditions
Tuberculosis
Interventions
Bronchoalveolar lavages and venipunctures only
Other
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 20, 2026, 2:23 PM EDT
Completed Phase 3 Interventional Results available

TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens

NCT02410772
View directory record Official record
Conditions
Tuberculosis
Interventions
rifapentine, rifapentine and moxifloxacin, control
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
12 Years and older
Enrollment
2,516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
5
States / cities
San Francisco, California • New York, New York • Fort Worth, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 20, 2026, 2:23 PM EDT
Completed No phase listed Observational

Comparing Expectorated and Induced Sputum and Pharyngeal Swabs for Cultures, AFB Smears, and Cytokines in Pulmonary Nontuberculous Mycobacterial Infection

NCT01150721
View directory record Official record
Conditions
Mycobacterium Infections, Non-tuberculous
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 80 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 2:23 PM EDT
Completed Phase 3 Interventional

Effectiveness of Rifabutin in the Treatment of Mycobacterium Avium Complex

NCT03164291
View directory record Official record
Conditions
Nontuberculous Mycobacterial Infections
Interventions
Rifabutin
Drug
Lead sponsor
The University of Texas Health Science Center at Tyler
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1984 – 2017
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 20, 2026, 2:23 PM EDT
Completed No phase listed Observational

Evaluation of Non-Inferiority of Two Fast Follower Nucleic Acid Amplification Tests

NCT02252198
View directory record Official record
Conditions
Tuberculosis
Interventions
Epistem Genedrive® and MolBio Truenat™
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 20, 2026, 2:23 PM EDT
Completed Phase 2 Interventional

TBTC Study 23C: Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz

NCT00023413
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Rifabutin, Efavirenz
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Oct 20, 2026, 2:23 PM EDT
Completed Phase 2 Interventional Results available

A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)

NCT00685360
View directory record Official record
Conditions
Tuberculosis, Pulmonary, Tuberculosis, Multidrug Resistant, Extensively Drug-Resistant Tuberculosis
Interventions
Delamanid, Optimized Background Regimen (OBR), Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Oct 20, 2026, 2:23 PM EDT
Recruiting No phase listed Observational

Training Protocol on the Natural History of Tuberculosis

NCT01212003
View directory record Official record
Conditions
Mycobacterium Infections, Tuberculosis, Multidrug-Resistant, Latent Tuberculosis, Tuberculosis, Extensively Drug-Resistant Tuberculosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 100 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 20, 2026, 2:23 PM EDT
Completed No phase listed Observational

Sputum Pharmacokinetics of TB Drugs and Bacterial Drug Resistance

NCT02534727
View directory record Official record
Conditions
Tuberculosis, Non-Tuberculosis Mycobacteria
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 20, 2026, 2:23 PM EDT
Completed Phase 4 Interventional

TBTC Study 23B:Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB

NCT00023400
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Nelfinavir, Rifabutin
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
0 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2005 · Synced Oct 20, 2026, 2:23 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Dose Study of Tuberculin Purified Protein Derivative (JHP/Dose)

NCT01689831
View directory record Official record
Conditions
Tuberculosis Infection
Interventions
To confirm the potency of Aplisol formulated with newly produced Tuberculin PPD compared to PPD-S2 standard., Reactivity of Aplisol compared to reference standard PPD-S2.
Biological
Lead sponsor
JHP Pharmaceuticals LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2012 · Synced Oct 20, 2026, 2:23 PM EDT
Withdrawn Not applicable Interventional

Comparison of the Quantiferon®-TB GOLD (in Tube) Assay With Tuberculin Skin Testing for Detecting Latent Tuberculosis Infection in Patients With Chronic Liver Disease Being Evaluated for or Awaiting Liver Transplantation

NCT00424684
View directory record Official record
Conditions
Chronic Liver Disease, TB
Interventions
collection of blood sample
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Oct 20, 2026, 2:23 PM EDT
Completed Phase 1 Interventional

Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis

NCT00004736
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Nelfinavir mesylate, Ethambutol hydrochloride, Isoniazid, Pyrazinamide, Lamivudine, Rifabutin, Stavudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2008 · Synced Oct 20, 2026, 2:23 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects

NCT00743470
View directory record Official record
Conditions
HIV, Tuberculosis
Interventions
lopinavir/ritonavir, rifabutin
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Waukegan, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 2, 2010 · Synced Oct 20, 2026, 2:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Evaluation of the QuantiFERON-TB Test.

NCT02256839
View directory record Official record
Conditions
Tuberculosis
Interventions
CST_001
Device
Lead sponsor
QIAGEN Gaithersburg, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
268 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 20, 2026, 2:23 PM EDT
Completed Phase 2 Interventional

TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of Tuberculosis

NCT00023426
View directory record Official record
Conditions
Tuberculosis
Interventions
rifapentine
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2005 · Synced Oct 20, 2026, 2:23 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections

NCT04884308
View directory record Official record
Conditions
Cystic Fibrosis, Bronchiectasis Adult, Non-Tuberculous Mycobacteria
Interventions
BCG TICE Vaccine
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 20, 2026, 2:23 PM EDT
Withdrawn No phase listed Observational

Video Based Directly Observed Therapy for Latent TB

NCT03783728
View directory record Official record
Conditions
Latent Tuberculosis
Interventions
Rifapentine 600 mg orally, Isoniazid 900 mg orally, Pyridoxine 50 mg orally
Drug
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Oct 20, 2026, 2:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects

NCT04865536
View directory record Official record
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Interventions
TBI-223 1800 mg, TBI-223 2400mg, TBI-223 Placebo
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 20, 2026, 2:23 PM EDT
Completed Phase 2 Interventional Results available

A Proof of Concept Study of Inhaled Nitric Oxide for Adults With Pulmonary Non-Tuberculous Mycobacterial Infection

NCT03748992
View directory record Official record
Conditions
Nontuberculous Mycobacterium Infection
Interventions
gNO
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Portland, Oregon • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 20, 2026, 2:23 PM EDT
Completed Phase 2 Interventional

TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment

NCT00144417
View directory record Official record
Conditions
Tuberculosis
Interventions
Moxifloxacin (with rifampin, pyrazinamide, and ethambutol), isoniazid
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Oct 20, 2026, 2:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Screening for Latent Tuberculosis Infection (LTBI) in US Army Recruits

NCT00804713
View directory record Official record
Conditions
Latent Tuberculosis Infection
Interventions
BST, TST, QFT, T-spot
Drug · Other
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
2,017 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2022
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 20, 2026, 2:23 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy

NCT03819114
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Levonorgestrel (LNG)
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
16 Years and older · Female only
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
7
States / cities
Chicago, Illinois • New York, New York • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2021 · Synced Oct 20, 2026, 2:23 PM EDT